Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Dermatitis ; 31(6): 335-349, 2020.
Artículo en Inglés | MEDLINE | ID: mdl-33186331

RESUMEN

: Cutaneous exposure to aluminum may occur via contact with metal items, medications, and personal care products. Despite the widespread use of aluminum, allergic contact dermatitis is relatively rare. Sensitization is often incidentally identified during patch testing with aluminum-based chambers. This article presents several cases along with a literature review summarizing prevalence and clinical manifestations of cutaneous reactions to aluminum, recommendations for patch testing, sources of aluminum, and reproducibility of aluminum allergy over time.


Asunto(s)
Aluminio/efectos adversos , Dermatitis Alérgica por Contacto/etiología , Antiácidos/química , Antitranspirantes/química , Desensibilización Inmunológica , Humanos , Tatuaje , Pastas de Dientes/química , Vacunas/química
3.
Neurotox Res ; 35(2): 353-359, 2019 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-30259417

RESUMEN

Autism spectrum disorder (ASD) is a neurodevelopmental disorder, characterized by cognitive and sensorimotor deficits, among others. Hypo-sensitivity and hyper-sensitivity to different stimuli within the same sensory modality, a prominent symptom of ASD, can be assessed by acoustic startle response (ASR) and prepulse inhibition (PPI). Propionic acid (PPA) is a short-chain fatty acid and a by-product of the human gut microbiome. Rodents treated with PPA has been found to produce ASD-related behavioral abnormalities, gastrointestinal discomfort, and conditioned aversions. The present study examined ASR and PPI in adult male rats treated systemically (intraperitoneal injections) with two different doses of PPA. A single injection of PPA produced significant dose-dependent reductions in startle response magnitude relative to control rats. However, PPA-treated rats did not show significant sensorimotor gating abnormalities relative to controls, based on the PPI measures. These findings add to the growing body of evidence supporting the validity of the PPA rodent model of ASD.


Asunto(s)
Trastorno del Espectro Autista/tratamiento farmacológico , Fermentación , Microbioma Gastrointestinal , Propionatos/administración & dosificación , Reflejo de Sobresalto/efectos de los fármacos , Filtrado Sensorial/efectos de los fármacos , Estimulación Acústica/efectos adversos , Animales , Trastorno del Espectro Autista/fisiopatología , Relación Dosis-Respuesta a Droga , Masculino , Distribución Aleatoria , Ratas , Ratas Long-Evans , Reflejo de Sobresalto/fisiología , Filtrado Sensorial/fisiología , Resultado del Tratamiento
5.
Psychopharmacology (Berl) ; 232(20): 3841-8, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-26297326

RESUMEN

RATIONALE: Fatty acid amide hydrolase (FAAH) inhibition elevates anandamide (AEA), which acts on cannabinoid (CB1 and CB2) receptors, as well as N-palmitoylethanolamide (PEA) and N-oleoylethanolamine (OEA), which act on peroxisome proliferator-activated receptor alpha (PPARα). Here, we determine the mechanism of action of FAAH inhibition on acute and anticipatory nausea (AN). OBJECTIVE: We compared the effectiveness and mechanism of action of two FAAH inhibitors, URB597 and PF-3845, to reduce acute nausea and AN in rodent models of conditioned gaping. MATERIALS AND METHODS: For assessment of acute nausea, rats were pretreated with vehicle (VEH), URB597 (0.3 and 10 mg/kg, experiment 1a) or PF-3845 (10 mg/kg, experiment 1b) 120 min prior to a saccharin-lithium chloride (LiCl) pairing. To assess the CB1 receptor or PPARα mediation of the effect of PF-3845 on acute nausea, rats were also pretreated with rimonabant or MK886, respectively. For assessment of AN, following four pairings of a novel context with LiCl, rats received a pretreatment of VEH, URB597 (0.3 mg/kg, experiment 2a), or PF-3845 (10, 20 mg/kg, experiment 2b) 120 min prior to placement in the AN context. To assess the CB1 receptor or PPARα mediation of the effect, rats were also pretreated with rimonabant or MK886, respectively. RESULTS: PF-3845 (10 mg/kg, but not URB597 0.3 or 10 mg/kg) suppressed acute nausea via PPARα, but not CB1 receptors. URB597 (0.3 and 10 mg/kg) or PF-3845 (10 and 20 mg/kg) reduced AN via CB1 receptors, but not PPARα. CONCLUSIONS: FAAH inhibition reduces acute nausea and AN through PPARα and CB1 receptor mediated effects, respectively.


Asunto(s)
Amidohidrolasas/antagonistas & inhibidores , Anticipación Psicológica/fisiología , Náusea/prevención & control , PPAR alfa/fisiología , Receptor Cannabinoide CB1/fisiología , Enfermedad Aguda , Amidohidrolasas/metabolismo , Animales , Anticipación Psicológica/efectos de los fármacos , Benzamidas/farmacología , Benzamidas/uso terapéutico , Carbamatos/farmacología , Carbamatos/uso terapéutico , Masculino , Náusea/metabolismo , Piperidinas/farmacología , Piperidinas/uso terapéutico , Piridinas/farmacología , Piridinas/uso terapéutico , Ratas , Ratas Sprague-Dawley
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA